Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
ALTEOGEN signed an exclusive license agreement with Biogen International GMBH (a subsidiary of Biogen Inc.) to develop and commercialize subcutaneous (SC) formulations of two Biogen biopharmaceutical products using human hyaluronidase (ALT-B4). The total deal value is up to USD 579M (approx. KRW 867.5B, excluding sales royalties).
📊 [Key Disclosure Details & Major Figures Summary]
- Counterparty: Biogen International GMBH (Switzerland, subsidiary of Biogen Inc. / Biogen Inc. FY2025 Revenue: USD 9,891M, approx. KRW 14.8T)
- Contract Details: Exclusive license agreement for the development and commercialization of subcutaneous formulations for two Biogen biopharmaceutical products applying ALTEOGEN’s Hybrozyme platform-based human hyaluronidase (ALT-B4)
- Contract Date / Duration: March 25, 2026 / Until the expiration of the royalty period
- Financial Details:
- Upfront Payment: USD 20,000,000 (Approx. KRW 30.0B)
- Additional USD 10,000,000 (Approx. KRW 15.0B) upon selection of the second product
- Milestones: Up to USD 549,000,000 (Approx. KRW 822.6B) upon achieving clinical, regulatory, and commercial milestones
- Total Potential Contract Value (Upfront + Milestones): Up to USD 579,000,000 (Approx. KRW 867.5B, excluding sales royalties)
- Sales Royalties: Royalties based on a percentage of net sales following the first commercial sale
- Upfront Payment: USD 20,000,000 (Approx. KRW 30.0B)
- Key Terms & Conditions:
- Refund Terms: No refund obligations for upfront payments, milestones, or royalties (Upfront payment scheduled to be received within 10 business days from agreement execution)
- Option Terms: Biogen holds an option to develop one additional product beyond the initial two products (Total deal value may increase if the option is exercised)
- Exchange Rate Applied: KRW 1,498.30/USD (SEOUL MONEY BROKERAGE notice rate on March 25, 2026)
- Investment Risk Warning: Revenue recognition depends on the success of clinical trials and regulatory approvals; agreement may be terminated upon clinical failure or regulatory halt
- Non-disclosure Notice: Detailed breakdown of contract figures (specific targets, detailed milestones, royalty rates) is withheld under confidentiality obligations
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Upfront Payment Receipt and Milestone Progress
This disclosure formally announces an exclusive license-out agreement for ALTEOGEN’s proprietary human hyaluronidase platform (ALT-B4). Confirming the receipt of the upfront payment scheduled within 10 business days and tracking the progress of subsequent clinical and regulatory milestones is essential because it allows investors to verify the actual implementation and execution of the licensing agreement. Detailed updates can be cross-checked in subsequent disclosure filings and periodic reports (Quarterly, Half-Yearly, and Annual Reports).
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
